- In May 2023, The Drugs for Neglected Diseases initiative (DNDi) partnered with the University of Dundee to develop new oral treatments for bejel and yaws. This collaboration combines DNDi's expertise in drug development with the University’s research on macrolide antibiotics, aiming to create effective treatments for these neglected tropical diseases
- In October 2022, The Medicines for Malaria Venture (MMV) announced the start of a Phase III clinical trial for MMV0877, a new single-dose oral treatment for bejel. This trial, in collaboration with the University of Texas Medical Branch, aims to evaluate the treatment’s efficacy, with completion anticipated by 2025, offering hope for a simpler cure
